Medicine Press release

OMRON Healthcare Co., Ltd., a global leader in clinically proven medical devices for home health monitoring and treatment, today announced the integration of its ECG-enabled upper arm blood pressure monitors with Tricog Health Pte. Ltd.'s clinically validated AI-powered cardiac triage service, Tricog CardioCheck (TCC). The service is launched in April 2026.
More info..

OMRON Healthcare Co., Ltd., a global leader in clinically proven medical devices for home health monitoring and treatment, today announced the integration of its ECG-enabled upper arm blood pressure monitors with Tricog Health Pte. Ltd.'s clinically validated AI-powered cardiac triage service, Tricog CardioCheck (TCC). The service is launched in April 2026.
More info..

Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada), and Eisai (Headquarters: Tokyo, CEO: Haruo Naito) today announced results from the Phase 3 LITESPARK-012 trial evaluating combination treatments for the firstline treatment of patients with advanced clear cell renal cell carcinoma (RCC).
More info..

Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Bio B.V., a wholly owned subsidiary of NEC Corporation, a leader in IT, network and AI technologies, announce the signing of a license agreement to advance the clinical development of TG4050, an individualized neoantigen therapeutic vaccine (INTV) in the adjuvant treatment of resected HPV-negative head and neck cancer.
More info..

Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Bio B.V., a wholly owned subsidiary of NEC Corporation, a leader in IT, network and AI technologies, announce the signing of a license agreement to advance the clinical development of TG4050, an individualized neoantigen therapeutic vaccine (INTV) in the adjuvant treatment of resected HPV-negative head and neck cancer.
More info..

Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Bio B.V., a wholly owned subsidiary of NEC Corporation, a leader in IT, network and AI technologies, announce the signing of a license agreement to advance the clinical development of TG4050, an individualized neoantigen therapeutic vaccine (INTV) in the adjuvant treatment of resected HPV-negative head and neck cancer.
More info..

Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Bio B.V., a wholly owned subsidiary of NEC Corporation, a leader in IT, network and AI technologies, announce the signing of a license agreement to advance the clinical development of TG4050, an individualized neoantigen therapeutic vaccine (INTV) in the adjuvant treatment of resected HPV-negative head and neck cancer.
More info..

OMRON Healthcare Co., Ltd. today announced the launch of a randomized controlled trial in collaboration with the University of California, San Francisco (UCSF) to evaluate a new model for the early detection of atrial fibrillation (AFib) in hypertension patients using home blood pressure monitoring.
More info..

OMRON Healthcare Co., Ltd. today announced the launch of a randomized controlled trial in collaboration with the University of California, San Francisco (UCSF) to evaluate a new model for the early detection of atrial fibrillation (AFib) in hypertension patients using home blood pressure monitoring.
More info..

Across the landscape of global biotech companies, the appointment of a senior executive often serves as a "barometer"-offering insights into a company's pipeline potential and reflecting how industry veterans gauge the sector's future.
More info..